Vanda Pharmaceuticals Inc.
Use of tradipitant in motion sickness
Last updated:
Abstract:
Disclosed herein is a method of treating or preventing motion sickness or at least one symptom thereof, comprising treatment with the NK-1 receptor antagonist, tradipitant.
Status:
Grant
Type:
Utility
Filling date:
3 Oct 2019
Issue date:
3 Nov 2020